Featured Articles

  1. Practical Strategies For Diverse Trial Recruitment 11/11/2024

    The clock is ticking on the requirement for pharmaceutical companies to include FDA-mandated diversity action plans for pivotal studies in clinical trials.

  2. Maturity Model For Clinical Trial Disclosure 11/11/2024

    Learn about the eight key domains that are assessed by the clinical trial disclosure maturity model.

  3. Transforming Clinical Trial Disclosure With AI 10/23/2024

    Unlock the full potential of AI to address sponsor challenges including regulatory complexity, clinical trial disclosure requirements, and growing demands for transparency.

  4. AI in Pharma: Benefits, Risks, And The Road Ahead 10/23/2024

    How could leveraging AI technologies, including machine learning (ML) and generative AI (GenAI), enable your company to streamline processes from drug discovery to post-launch?

  5. A Promising Rebound in Clinical Trials 10/23/2024

    This report explores how clinical trials bounced back in 2023 from their decline a year earlier despite continued geopolitical, regulatory, and pricing pressures.

  6. The Importance Of A Maturity Model For Clinical Trial Transparency 10/23/2024

    A comprehensive maturity model for clinical trial disclosure and transparency offers companies a strategic tool to assess and enhance their practices in an increasingly complex regulatory environment.

  7. A Guide To Patient Engagement And Recruitment Solutions 10/7/2024

    In this text we explore strategic solutions to patient recruitment and engagement challenges, emphasizing the importance of comprehensive patient engagement and recruitment strategies.

  8. Synthetic Data's Value In Clinical Research 9/16/2024

    Synthetic data is a form of generative artificial intelligence (AI) that, in the life sciences, is especially valuable for enhancing datasets and increasing diversity in clinical trials.

  9. Diversity At The Start: Best Practices For Clinical Trial Planning 9/9/2024

    Claire Riches, Citeline's VP of Clinical Solutions, emphasizes that clinical trial diversity must start with a fit-for-purpose protocol, incorporating the patient voice early on to ensure success in reaching diverse populations.

  10. Clinical Trial Diversity From A Disclosure Perspective 9/9/2024

    Although the FDA mandate on diversity action plans won’t come until 2025, sponsors should start planning how to be inclusive, increasing the representation of underrepresented groups in clinical trials and reporting that data.